

# silenceworks

BENITEC'S PROGRESS IN SILENCE

## Market Snapshot

### Market Data as at March 27, 2014

ASX Code:	BLT
Share Price:	AUD1.85
Market Cap:	AUD185.2million
52 week high/low:	AUD2.38/0.28*
Shares on issue:	100,115,987
Industry sector :	Biotechnology

\* Converted to post consolidation pricing

### In this issue

- ▶ Benitec to raise AUD31.5 million to accelerate programs
- ▶ A Frenetic Fortnight In February: CEO Update
- ▶ Lodge raises target price to AUD3.20 and retains 'BUY'
- ▶ Benitec appoints Chief Medical Adviser for lung cancer program
- ▶ Benitec continues profile-raising with global investors & media

## GENERAL MEETING

To approve the second tranche of AUD31.5m Private Placement

**11.00am, Thursday April 10, 2014**  
Lvl 17, 383 Kent Street, Sydney 2000



### Benitec to raise AUD31.5m to accelerate programs

As Benitec prepares to dose patients in the 'first in man' clinical trial of TT-034 for hepatitis C, the company has secured agreements to raise AUD31.5 million to advance this and other programs towards and into the clinic. This strong support from leading international institutional funds, including RA Capital Management, reflects recognition of Benitec's technology and programs, and strong investor interest in gene silencing worldwide.

[Read the ASX Announcement](#) ▶

A **General Meeting** will be held on April 10, 2014 to approve the second tranche of the funding. The Benitec Board of Directors unanimously recommends that shareholders vote to approve the funding, which has the potential to transform Benitec into a company with multiple clinical stage assets.



### A frenetic fortnight in february: CEO update

CEO and MD Dr Peter French reflects on the strategies and market forces that came together at a critical point in February 2014. He explains how Benitec has been pursuing a deliberate strategy to promote itself to a global audience and to attract the attention of international institutional and large pharmaceutical companies. In late February 2014, Benitec came onto the radar of some of the world's largest institutional funds and the positive impact on the share register and price was dramatic.

[Read the CEO Update](#) ▶



### Lodge raises target price to AUD3.20 and retains 'BUY'

In its March 14 update on Benitec, Lodge Partners Research commented on the AUD31.5m capital raise. Lodge said that the raise is a strong positive signal from international institutional investors, and positions the company to take advantage of opportunities from a strong balance sheet, and to create very significant value for shareholders in the next year. In addition, Lodge also raised its price target to AUD3.20 and retained its 'buy' recommendation. [Read the full Research Note](#) ▶



### Benitec appoints Chief Medical Adviser for lung cancer program

The company has appointed Associate Professor Craig Lewis as Chief Medical Adviser on our non-small cell lung cancer program in collaboration with the Children's Cancer Institute Australia at the University of NSW. Dr Lewis is a medical oncologist at Sydney's Prince of Wales Hospital. In his new role, he will assist with preparation of the clinical trial for Tribetarna™. [Read the ASX Announcement](#) ▶



### Benitec continues profile-raising with global investors & media

Over January and March the management team presented the **business and investment case** for Benitec at variety of international investor events: CEO Dr Peter French presented at *Biotech Showcase* in San Francisco; CBO Carl Stubbings at *BioCEO* in New York and *ASX Spotlight* in London, and SVP R&D Dr David Suhy at *ASX Spotlight* in New York. In addition, Peter French talked to [Jon Faine on ABC radio 774](#) about the impact that biotechs like Benitec might have on Australia's manufacturing industry, and put the upcoming clinical trial into context with American Airlines 'Talk Business 360.'